In a recent development, Nona Biosciences has formed a partnership with Lycia Therapeutics, a prominent player in breaking down proteins outside cells. Lycia, known for its lysosomal targeting chimeras (LYTACs) platform, aims to discover and develop treatments that break down proteins associated with challenging diseases. Through this collaboration, Lycia will utilize Nona’s Harbour Mice® HCAb fully human antibody transgenic mice platform to identify new antibodies for its LYTAC protein degrader treatments. Dr. Jingsong Wang, Chairman of Nona Biosciences, anticipates that this collaboration will accelerate Lycia’s progress in creating innovative protein degrader treatments. Dr. Steve Staben, Chief Scientific Officer of Lycia Therapeutics, highlights the unique capabilities of LYTACs in addressing extracellular disease targets. The overarching goal of this partnership is to leverage Nona Biosciences’ technology to discover treatments for patient groups often overlooked in medical research.

Nona Biosciences, a global biotech company and a wholly-owned subsidiary of HBM Holdings Limited, provides comprehensive solutions for biotech innovation. From confirming targets to finding antibodies and conducting preclinical research, Nona Biosciences employs the Harbour Mice® technology, producing fully human monoclonal antibodies. Positioned globally, the company aims to contribute to the development of groundbreaking next-gen drugs. The collaboration between Nona Biosciences and Lycia Therapeutics marks a significant step in addressing challenging diseases globally. Their combined expertise and use of advanced technologies offer hope for effective treatments for underserved patient populations.